ERAS | Ticker Profile - Titan Protect

ERAS

Erasca, Inc.

Healthcare · Biotechnology · NMS

$11.97

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$3.9B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-22.11

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-69.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$20.50

+71% from current price — median analyst estimate

Recommendation

BUY

Consensus view from 10 analysts covering this stock

About Erasca, Inc.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

https://www.erasca.com

Country: United States Employees: 103 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

1.351

Excellent risk-adjusted returns

Kelly Fraction

0.0829

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

1.863

Returns exceed worst-case losses — strong risk profile

Annual Return

126.1%

Historical annualised return based on price data

Max Drawdown

-67.7%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.68

Less volatile than the market — more defensive

52W High

$24.28

51% below the year high

52W Low

$1.12

969% above the year low

Avg Volume

6,773,442

Average daily shares traded — higher means easier to buy and sell

Short Ratio

3.4

Days it would take all short sellers to cover — higher means more crowded

Short % Float

11.3%

Elevated short interest — bears are positioned against this

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.93

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

11.68

Heavy leverage — higher financial risk if revenues decline

Current Ratio

9.52

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

9.27

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-212,711,744

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-277,020,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$30.00

Target Median

$20.50

Target Low

$9.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go